Literature DB >> 21986992

Tumor biomarker glycoproteins in the seminal plasma of healthy human males are endogenous ligands for DC-SIGN.

Gary F Clark1, Paola Grassi, Poh-Choo Pang, Maria Panico, David Lafrenz, Erma Z Drobnis, Michael R Baldwin, Howard R Morris, Stuart M Haslam, Sophia Schedin-Weiss, Wei Sun, Anne Dell.   

Abstract

DC-SIGN is an immune C-type lectin that is expressed on both immature and mature dendritic cells associated with peripheral and lymphoid tissues in humans. It is a pattern recognition receptor that binds to several pathogens including HIV-1, Ebola virus, Mycobacterium tuberculosis, Candida albicans, Helicobacter pylori, and Schistosoma mansoni. Evidence is now mounting that DC-SIGN also recognizes endogenous glycoproteins, and that such interactions play a major role in maintaining immune homeostasis in humans and mice. Autoantigens (neoantigens) are produced for the first time in the human testes and other organs of the male urogenital tract under androgenic stimulus during puberty. Such antigens trigger autoimmune orchitis if the immune response is not tightly regulated within this system. Endogenous ligands for DC-SIGN could play a role in modulating such responses. Human seminal plasma glycoproteins express a high level of terminal Lewis(x) and Lewis(y) carbohydrate antigens. These epitopes react specifically with the lectin domains of DC-SIGN. However, because the expression of these sequences is necessary but not sufficient for interaction with DC-SIGN, this study was undertaken to determine if any seminal plasma glycoproteins are also endogenous ligands for DC-SIGN. Glycoproteins bearing terminal Lewis(x) and Lewis(y) sequences were initially isolated by lectin affinity chromatography. Protein sequencing established that three tumor biomarker glycoproteins (clusterin, galectin-3 binding glycoprotein, prostatic acid phosphatase) and protein C inhibitor were purified by using this affinity method. The binding of DC-SIGN to these seminal plasma glycoproteins was demonstrated in both Western blot and immunoprecipitation studies. These findings have confirmed that human seminal plasma contains endogenous glycoprotein ligands for DC-SIGN that could play a role in maintaining immune homeostasis both in the male urogenital tract and the vagina after coitus.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21986992      PMCID: PMC3270097          DOI: 10.1074/mcp.M111.008730

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  89 in total

1.  DC-SIGN mediates binding of dendritic cells to authentic pseudo-LewisY glycolipids of Schistosoma mansoni cercariae, the first parasite-specific ligand of DC-SIGN.

Authors:  Sandra Meyer; Ellis van Liempt; Anne Imberty; Yvette van Kooyk; Hildegard Geyer; Rudolf Geyer; Irma van Die
Journal:  J Biol Chem       Date:  2005-09-09       Impact factor: 5.157

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  DC-SIGN binds ICAM-3 isolated from peripheral human leukocytes through Lewis x residues.

Authors:  Valentina Bogoevska; Peter Nollau; Lothar Lucka; Detlef Grunow; Birgit Klampe; Liisa M Uotila; Alexandra Samsen; Carl G Gahmberg; Christoph Wagener
Journal:  Glycobiology       Date:  2006-12-04       Impact factor: 4.313

4.  CEACAM1, an adhesion molecule of human granulocytes, is fucosylated by fucosyltransferase IX and interacts with DC-SIGN of dendritic cells via Lewis x residues.

Authors:  Valentina Bogoevska; Andrea Horst; Birgit Klampe; Lothar Lucka; Christoph Wagener; Peter Nollau
Journal:  Glycobiology       Date:  2005-11-10       Impact factor: 4.313

5.  Expression of clusterin in human pancreatic cancer.

Authors:  Min-Jue Xie; Yoshiharu Motoo; Shi-Bing Su; Hisatsugu Mouri; Koushiro Ohtsubo; Fujitsugu Matsubara; Norio Sawabu
Journal:  Pancreas       Date:  2002-10       Impact factor: 3.327

6.  The heterodimeric structure of glucosidase II is required for its activity, solubility, and localization in vivo.

Authors:  M F Pelletier; A Marcil; G Sevigny; C A Jakob; D C Tessier; E Chevet; R Menard; J J Bergeron; D Y Thomas
Journal:  Glycobiology       Date:  2000-08       Impact factor: 4.313

7.  Analysis of protein-linked glycosylation in a sperm-somatic cell adhesion system.

Authors:  Mark Sutton-Smith; Nyet Kui Wong; Kay-Hooi Khoo; Sz-Wei Wu; Shin-Yi Yu; Manish S Patankar; Richard Easton; Frank A Lattanzio; Howard R Morris; Anne Dell; Gary F Clark
Journal:  Glycobiology       Date:  2007-03-02       Impact factor: 4.313

Review 8.  Protein C inhibitor, a serpin with functions in- and outside vascular biology.

Authors:  Margarethe Geiger
Journal:  Thromb Haemost       Date:  2007-03       Impact factor: 5.249

9.  Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer.

Authors:  S Iacobelli; E Arnò; A D'Orazio; G Coletti
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

10.  The expression of free oligosaccharides in human seminal plasma.

Authors:  Sara Chalabi; Richard L Easton; Manish S Patankar; Frank A Lattanzio; Jamie C Morrison; Maria Panico; Howard R Morris; Anne Dell; Gary F Clark
Journal:  J Biol Chem       Date:  2002-06-12       Impact factor: 5.157

View more
  12 in total

Review 1.  The role of glycans in immune evasion: the human fetoembryonic defence system hypothesis revisited.

Authors:  Gary F Clark
Journal:  Mol Hum Reprod       Date:  2013-09-15       Impact factor: 4.025

2.  Unusual N-type glycosylation of salivary prolactin-inducible protein (PIP): multiple LewisY epitopes generate highly-fucosylated glycan structures.

Authors:  Alena Wiegandt; Henning N Behnken; Bernd Meyer
Journal:  Glycoconj J       Date:  2018-06-01       Impact factor: 2.916

3.  Investigation of galectin-3 function in the reproductive tract by identification of binding ligands in human seminal plasma.

Authors:  Matthew R Kovak; Sarika Saraswati; David J Schoen; Alan B Diekman
Journal:  Am J Reprod Immunol       Date:  2014-05-23       Impact factor: 3.886

4.  Site-specific glycoforms of haptoglobin in liver cirrhosis and hepatocellular carcinoma.

Authors:  Petr Pompach; Zuzana Brnakova; Miloslav Sanda; Jing Wu; Nathan Edwards; Radoslav Goldman
Journal:  Mol Cell Proteomics       Date:  2013-02-06       Impact factor: 5.911

5.  Attenuation of fibroblast growth factor signaling by poly-N-acetyllactosamine type glycans.

Authors:  Kazuhiro Sugihara; Toshiaki K Shibata; Kayoko Takata; Takako Kimura; Naohiro Kanayama; Roy Williams; Shingo Hatakeyama; Tomoya O Akama; Chu-Wei Kuo; Kay-Hooi Khoo; Michiko N Fukuda
Journal:  FEBS Lett       Date:  2013-08-19       Impact factor: 4.124

6.  N-glycans of human protein C inhibitor: tissue-specific expression and function.

Authors:  Wei Sun; Paola Grassi; Ake Engström; Sanjeewani Sooriyaarachchi; Wimal Ubhayasekera; Julius Hreinsson; Kjell Wånggren; Gary F Clark; Anne Dell; Sophia Schedin-Weiss
Journal:  PLoS One       Date:  2011-12-19       Impact factor: 3.240

Review 7.  Reversed-phase separation methods for glycan analysis.

Authors:  Gerda C M Vreeker; Manfred Wuhrer
Journal:  Anal Bioanal Chem       Date:  2016-11-25       Impact factor: 4.142

Review 8.  Functional glycosylation in the human and mammalian uterus.

Authors:  Gary F Clark
Journal:  Fertil Res Pract       Date:  2015-10-23

9.  Aberrant fucosylation enables breast cancer clusterin to interact with dendritic cell-specific ICAM-grabbing non-integrin (DC-SIGN).

Authors:  Antonela Merlotti; Alvaro López Malizia; Paula Michea; Pierre-Emmanuel Bonte; Christel Goudot; María Sol Carregal; Nicolás Nuñez; Christine Sedlik; Ana Ceballos; Vassili Soumelis; Sebastián Amigorena; Jorge Geffner; Eliane Piaggio; Juan Sabatte
Journal:  Oncoimmunology       Date:  2019-06-24       Impact factor: 8.110

10.  Manifestations of immune tolerance in the human female reproductive tract.

Authors:  Gary F Clark; Danny J Schust
Journal:  Front Immunol       Date:  2013-02-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.